A Dietary Anthocyanidin Delphinidin Induces Apoptosis of Human Prostate Cancer PC3 Cells In vitro and In vivo: Involvement of Nuclear Factor-κB Signaling

被引:168
作者
Bin Hafeez, Bilal [1 ]
Siddiqui, Imtiaz Ahmad [1 ]
Asim, Mohammad [1 ]
Malik, Arshi [1 ]
Afaq, Farrukh [1 ]
Adhami, Vaqar Mustafa [1 ]
Saleem, Mohammad [1 ]
Din, Maria [1 ]
Mukhtar, Hasan [1 ]
机构
[1] Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA
关键词
D O I
10.1158/0008-5472.CAN-08-2232
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Delphinidin, a major anthocyanidin present in many pigmented fruits and vegetables, possesses antioxidant, anti-inflammatory, and antiangiogenic properties. In this study, we provide evidence that it could be developed as a novel agent against human prostate cancer (PCa). We observed that delphinidin treatment to human PCa LNCaP, C4-2, 22RvI, and PC3 cells resulted in a dose-dependent inhibition of cell growth without having any substantial effect on normal human prostate epithelial cells. We selected PC3 cells as a test model system because of their highly aggressive proliferative nature. Delphinidin treatment of cells resulted in a dose-dependent induction of apoptosis and arrest of cells in G(2)-M phase. This induction of apoptosis seems to be mediated via activation of caspases because N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluromethylketone significantly reduced apoptosis induced by delphinidin. We also observed that delphinidin treatment of cells resulted in a dose-dependent decrease in (a) phosphorylation of I kappa B kinase gamma (NENIO), (b) phosphorylation of nuclear factor-kappa B (NF-kappa B) inhibitory protein I kappa B alpha, (c) phosphorylation of NF-kappa B/p65 at Ser(536) and NF-kappa B/p50 at Ser(529), (d) NF-kappa B/p65 nuclear translocation, and (e) NF-kappa B DNA binding activity. Delphinidin administration (2 mg, i.p. thrice weekly) to athymic nude mice implanted with PC3 cells resulted in a significant inhibition of tumor growth. Analysis of tumors from delphinidin-treated mice showed significant decrease in the expression of NF-kappa B/p65, Bcl2, Ki67, and PCNA. Taken together, our data suggest that delphinidin could be developed as an agent against human PCa. [Cancer Res 2008;68(20):8564-72]
引用
收藏
页码:8564 / 8572
页数:9
相关论文
共 43 条
  • [21] Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation
    Lamy, S
    Blanchette, M
    Michaud-Levesque, J
    Lafleur, R
    Durocher, Y
    Moghrabi, A
    Barrette, S
    Gingras, D
    Béliveau, R
    [J]. CARCINOGENESIS, 2006, 27 (05) : 989 - 996
  • [22] Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling
    Lamy, Sylvie
    Beaulieu, Edith
    Labbe, David
    Bedard, Valerie
    Moghrabi, Albert
    Barrette, Stephane
    Gingras, Denis
    Beliveu, Richard
    [J]. CARCINOGENESIS, 2008, 29 (05) : 1033 - 1041
  • [23] Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer
    Malik, A
    Afaq, F
    Sarfaraz, S
    Adhami, VM
    Syed, DN
    Mukhtar, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (41) : 14813 - 14818
  • [24] ANTHOCYANINS IN GRAPES AND GRAPE PRODUCTS
    MAZZA, G
    [J]. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 1995, 35 (04) : 341 - 371
  • [25] McDonald ER, 2000, INT J ONCOL, V16, P871
  • [26] Cell cycle checkpoints and their inactivation in human cancer
    Molinari, M
    [J]. CELL PROLIFERATION, 2000, 33 (05) : 261 - 274
  • [27] Caspase structure, proteolytic substrates, and function during apoptotic cell death
    Nicholson, DW
    [J]. CELL DEATH AND DIFFERENTIATION, 1999, 6 (11) : 1028 - 1042
  • [28] Antioxidant activities of pomegranate fruit extract and its anthocyanidins: Delphinidin, cyanidin, and pelargonidin
    Noda, Y
    Kaneyuki, T
    Mori, A
    Packer, L
    [J]. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2002, 50 (01) : 166 - 171
  • [29] Cell cycle regulation in the G1 phase: A promising target for the development of new chemotherapeutic anticancer agents
    Owa, T
    Yoshino, H
    Yoshimatsu, K
    Nagasu, T
    [J]. CURRENT MEDICINAL CHEMISTRY, 2001, 8 (12) : 1487 - 1503
  • [30] Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012